PLX: Elfabrio Estimates Up, Again
Protalix BioTherapeutics, Inc. Q3 2026 Earnings Call Summary
Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript
Protalix: Q3 Earnings Snapshot
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
Protalix BioTherapeutics Q3 2026 Earnings Call Transcript
Protalix BioTherapeutics Affirms FY2026 Sales Guidance of $78.000M-$83.000M vs $71.359M Est
Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
Protalix Biotherapeutics To Present Individual Participant Results From PK And PD Analysis Of Higher-Dose Cohorts Of Its Phase 1 Single Ascending Dose Study Of PRX-115, At ACR Convergence 2026
Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary
PLX: Elfabrio Estimates Up
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.